ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.7% – Should You Sell?

ADMA Biologics Inc (NASDAQ:ADMA)’s share price dropped 8.7% during mid-day trading on Tuesday . The company traded as low as $12.41 and last traded at $12.4080. Approximately 4,620,968 shares traded hands during trading, an increase of 53% from the average daily volume of 3,028,221 shares. The stock had previously closed at $13.59.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA’s public rebuttal — ADMA issued a detailed statement calling the Culper Research report “misleading, false and inaccurate” and says the Board is reviewing the allegations; this is a defense that may reassure some investors. ADMA Biologics Addresses Misleading Short-Seller Report
• Positive Sentiment: Unusual call buying — There was a large spike in call‑option volume (≈22,398 calls, ~848% above typical daily call volume), which can indicate speculative buy interest or hedging by parties expecting volatility or a rebound. (market data)
• Positive Sentiment: Zacks added ADMA to a “Strong Buy” list shortly before the drop — a signal some traders may use as a counterpoint to the negative headlines. New Strong Buy Stocks for March 25th
• Neutral Sentiment: Significant short interest and reporting noise — Recent filings show a material increase in short interest (reported ~25.8M shares, ~11.3% of float) and some inconsistent short‑interest summaries across sources; higher short interest raises squeeze risk but also selling pressure. (market data)
• Negative Sentiment: Culper Research short report alleges channel stuffing and related‑party distributor — The core allegation claims reported 2025 growth is largely fabricated absent channel stuffing; that charge directly threatens revenue credibility and could trigger regulatory scrutiny. ADMA Biologics shares plunge on short seller allegations
• Negative Sentiment: Multiple law firms have opened securities‑fraud investigations and issued investor alerts — Glancy Prongay, Pomerantz, Holzer, BFA Law, Frank R. Cruz, Ademi LLP and others have notified shareholders; class‑action inquiries typically increase legal, disclosure and reputational risk. Glancy Prongay Wolke & Rotter LLP investigation notice
• Negative Sentiment: Cantor Fitzgerald action and analyst reaction — Coverage notes include a downgrade/negative reaction tied to the short report (research downgrades can amplify selling pressure). ADMA Biologics extends selloff as Cantor downgrades after short report
• Negative Sentiment: Price and volume shock — The stock experienced a sharp selloff and very high intraday volume after the short report; news articles and market commentaries report sizable daily declines, which can worsen liquidity‑driven volatility. ADMA Biologics Stock Slides

Analysts Set New Price Targets

Several research firms have issued reports on ADMA. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Finally, Zacks Research upgraded ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, ADMA Biologics currently has an average rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Stock Performance

The firm has a market cap of $1.97 billion, a price-to-earnings ratio of 13.82 and a beta of 0.51. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. The stock’s 50 day moving average is $15.95 and its 200 day moving average is $16.52.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same period in the previous year, the company posted $0.46 EPS. The firm’s quarterly revenue was up 18.4% on a year-over-year basis. Analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Activity at ADMA Biologics

In related news, Director Steve Elms purchased 7,000 shares of ADMA Biologics stock in a transaction that occurred on Thursday, March 5th. The shares were acquired at an average price of $15.67 per share, with a total value of $109,690.00. Following the completion of the transaction, the director directly owned 2,038,730 shares of the company’s stock, valued at $31,946,899.10. This represents a 0.34% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently modified their holdings of ADMA. State Street Corp boosted its stake in ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after buying an additional 35,614 shares in the last quarter. Sachem Head Capital Management LP boosted its stake in shares of ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after purchasing an additional 2,415,000 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of ADMA Biologics by 36.9% during the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after purchasing an additional 1,886,105 shares during the last quarter. Capital Research Global Investors increased its position in ADMA Biologics by 104.0% during the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after purchasing an additional 3,383,559 shares in the last quarter. Finally, Nuveen LLC lifted its stake in ADMA Biologics by 3.5% in the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock valued at $108,097,000 after purchasing an additional 202,245 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.